CJC-1295 research guide for Sásabe. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers trying to source CJC-1295 in Sásabe quickly find that local retail options are nearly impossible to find. This online-only market structure is actually an advantage for quality — top vendors differentiate through analytical documentation in ways local stores never could. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis showing HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. What follows is a sourcing and quality evaluation guide built specifically around CJC-1295, covering everything a Sásabe researcher needs to evaluate quality systematically.
CJC-1295 Mechanisms Explained
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Sásabe comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Before looking at individual vendors, build a clear picture of what a proper COA looks like — so you can identify whether a supplier meets the standard. A COA for CJC-1295 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. For Sásabe researchers evaluating new suppliers: a test quantity before committing to research volumes before placing larger orders is the accepted approach among experienced researchers. The lyophilised (freeze-dried) form of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Sásabe
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human therapeutic use by the FDA or equivalent agencies worldwide — all information here is educational. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — or 25mcg per insulin syringe unit. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that proper COA verification addresses. Researchers using CJC-1295 alongside other research compounds should review the available literature for documented interactions before proceeding with any multi-compound protocol.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
